Differential effects of renin-angiotensine-aldosteron system inhibition, sympathoinhibition and low sodium diet on blood pressure in women with a history of preeclampsia: A double-blind, placebo-controlled cross-over trial (the PALM study)

Pregnancy Hypertens. 2022 Mar:27:173-175. doi: 10.1016/j.preghy.2021.12.016. Epub 2022 Jan 6.

Abstract

Current guidelines lack sufficient evidence to recommend a specific blood pressure lowering strategy to prevent cardiovascular disease after preeclampsia. We conducted a double-blind cross-over trial to identify the most potent antihypertensive strategy: renin-angiotensin-aldosterone system (RAAS) inhibition (losartan), sympathoinhibition (moxonidine), low sodium diet and placebo (n = 10). Due to low inclusion rate our study stopped prematurely. Initiatory analyses showed no significant effect of antihypertensive strategy on office blood pressure and 24-hour blood pressure. However, nocturnal dipping was significantly higher on RAAS inhibition and low sodium diet compared to placebo and sympathoinhibition. Optimal cardiovascular prevention after preeclampsia should be further explored.

Keywords: Cross-over trial; Hypertension; Low sodium diet; Postpartum; Preeclampsia; Renin-angiotensin-aldosterone system inhibition; Sympathoinhibition.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Angiotensin II Type 1 Receptor Blockers / administration & dosage*
  • Blood Pressure
  • Cardiovascular Diseases / prevention & control*
  • Cross-Over Studies
  • Dietary Approaches To Stop Hypertension / methods
  • Double-Blind Method
  • Female
  • Gestational Age
  • Humans
  • Imidazoles / administration & dosage*
  • Losartan / administration & dosage*
  • Postpartum Period
  • Pre-Eclampsia* / diet therapy
  • Pre-Eclampsia* / drug therapy
  • Pregnancy
  • Renin-Angiotensin System / drug effects

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Imidazoles
  • moxonidine
  • Losartan